Stock GTHX G1 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
2.57 USD +4.90% Intraday chart for G1 Therapeutics, Inc. +16.82% -15.74%
Jul. 01 G1 Therapeutics Joins Russell 3000, Russell 2000 Indexes MT
Jul. 01 G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2000 Dynamic Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
G1 THERAPEUTICS ADDED TO THE RUSSELL 2000 AND 3000 INDEXES
AQ
G1 Therapeutics Joins Russell 3000, Russell 2000 Indexes
MT
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
AQ
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2000 Dynamic Index
CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2500 Growth Index
CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell Small Cap Comp Growth Index
CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2500 Index
CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 3000 Index
CI
Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating
MT
HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating
MT
Top Midday Decliners
MT
Wedbush Adjusts Price Target on G1 Therapeutics to $3 From $5, Maintains Outperform Rating
MT
Sector Update: Health Care Stocks Advance Premarket Monday
MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data
MT
Transcript : G1 Therapeutics, Inc. - Special Call
Top Premarket Decliners
MT
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
MT
G1 Therapeutics' breast cancer drug fails in late-stage trial
RE
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
GL
G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GTHX Stock
  4. News G1 Therapeutics, Inc.